Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia. Mort JF, Brighton D, DiBenedetto S, Wells L, et al. Eur J Haematol 2024 Nov 27. doi: 10.1111/ejh.14354.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Mort JF, Brighton D, DiBenedetto S, Wells L, et al. Evaluation of Gemtuzumab Ozogamicin and Anthracycline Dosing for Favorable Risk Acute Myeloid Leukemia. Eur J Haematol 2024 Nov 27. doi: 10.1111/ejh.14354.
PMID: 39601208